MaaT Pharma announced plans to formally request the European Medicines Agency reconsider its recent rejection of MaaT013, an innovative treatment designed specifically for severe acute graft‑versus‑host disease.
Two high‑impact studies published recently in Nature spotlight difficult-to-treat blood cancers, revealing fresh insight into possible treatment paths. Research group found that stifling ADSS2-driven AMP production restored leukemia cells' sensitivity to targeted therapies like BH3 mimetics.
In another breakthrough , scientists silenced the mutant NPM1 gene in AML cells, showing that it reset histone functions and slowed cancer growth.
Meanwhile, hospital staff at Aberdeen briefly handled a hazardous biological agent with HIV infection risk .